16 June 2022: Clinical Research
Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era
Mevlut Tamer Dincer 1ABCDEF , Zeynep Toker Dincer 2BCE* , Oguz Kagan Bakkaloglu 3CEF , Serkan Feyyaz Yalin 4BE , Sinan Trabulus 1ADE , Aykut Ferhat Celik 3AE , Nurhan Seyahi 1CDE , Mehmet Riza Altiparmak 1ACDEDOI: 10.12659/MSM.936497
Med Sci Monit 2022; 28:e936497
Table 2 The most common presenting symptoms and treatment characteristics of the patients.
| Crohn’s disease | Ulcerative colitis | |||||
|---|---|---|---|---|---|---|
| Patients with renal involvement (n=55) | Control group (n=45) | p | Patients with renal involvement (n=50) | Control group (n=60) | p | |
| Diarrhea ,% | 80.0 | 91.1 | 0.101 | 78.0 | 76.7 | 0.526 |
| Nocturnal diarrhea, % | 16.4 | 26.7 | 0.156 | 32.0 | 30.0 | 0.492 |
| Rectal bleeding, % | 27.3 | 20.0 | 0.710 | 92.0 | 85.0 | 0.257 |
| Abdominal pain, % | 72.7 | 66.7 | 0.330 | 46.0 | 56.7 | 0.779 |
| Tenesmus, % | 20.0 | 31.1 | 0.148 | 40.0 | 26.7 | 0.100 |
| Fever, % | 12.7 | 2.2 | 0.056 | 10.0 | 5.0 | 0.262 |
| 5-ASA derivatives, % | 89.1 | 75.6 | 0.073 | 98.0 | 100.0 | 0.455 |
| Systemic steroids, % | 67.3 | 53.3 | 0.155 | 52.0 | 45.0 | 0.464 |
| Budesonide, % | 27.3 | 24.4 | 0.748 | NA | NA | NA |
| Azathioprine/MTX, % | 92.7 | 82.2 | 0.108 | 36.0 | 28.3 | 0.390 |
| Anti-TNF, % | 49.1 | 20.0 | 12.0 | 5.0 | 0.182 | |
| Infliximab, % | 41.8 | 8.9 | 8.0 | 5.0 | 0.521 | |
| Adalimumab, % | 7.3 | 11.1 | 0.504 | 4.0 | 0.0 | 0.204 |
| 5-ASA – 5-aminosalicylic acid; MTX – methotrexate; NA – not applicable; TNF – tumor necrosis factor. Significant p values are written in bold. | ||||||